EZH2 and cancer: Interpreting the mechanism of EZH2 and DNMT1 conductor in cancer immunity throws light on the promising benefit of the combinational treatment of epigenetic-modifying drugs (such as EZH2 or DNMT1 inhibitor) and immunotherapy (such as TAMs modulator) in patients with cancer.